ArticleFrontiers in endocrinology2024
Elevated AIP is associated with the prevalence of MAFLD in the US adults: evidence from NHANES 2017-2018.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between the atherogenic index of plasma and metabolic-associated/nonalcoholic fatty liver disease: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- The association between atherogenic index of plasma (AIP) and ultrasound attenuation parameter (UAP) in Chinese adults: a cross-sectional study.Scientific reports · 2026Article
- Longitudinal cohort study on the dynamic changes of atherogenic index of plasma and the risk of cardiometabolic multimorbidity in middle - aged and elderly people.BMC cardiovascular disorders · 2026Article
- Association of atherogenic index of plasma and cardiometabolic index with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999-2018.Cardiovascular diabetology · 2026Article
- U-shaped association between TC/HDL-C ratio and the risk of metabolic dysfunction-associated fatty liver disease in older adults.European journal of medical research · 2026Article
- Association between the atherogenic index of plasma and prehypertension or hypertension among adults in Fujian, China: a population-based cross-sectional study.Frontiers in cardiovascular medicine · 2026Article
- Association Between Thyroid Function Indicators and Metabolic-Associated Fatty Liver Disease: Effect Modification by Iodine Nutritional Status.International journal of endocrinology · 2026Article
- Atherogenic index of plasma as a simple marker for NAFLD risk stratification in community-dwelling older adults: a cross-sectional study with incremental predictive value assessment.Frontiers in endocrinology · 2026Article
- The correlation between the trajectory of plasma atherosclerosis-inducing index in the examination population and the risk of developing metabolic dysfunction-associated steatotic liver disease.Frontiers in endocrinology · 2026Article
- The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study.Frontiers in nutrition · 2026Article
- Periodontitis, Dyslipidemia and Rheumatoid Arthritis: An Additive Model of Cardiovascular Risk.Journal of clinical medicine · 2025Article
- Relationship between plasma atherogenic index and thyroid function: evidence from NHANES 2007-2012.Scientific reports · 2025Article
- Association between estimated glucose disposal rate and the risk of MAFLD in American adults: a cross-sectional study.Scientific reports · 2025Article
- Nonlinear association of physical activity with early cardiovascular-kidney-metabolic syndrome risk: a comprehensive analysis of NHANES data from 2007 to 2018.BMC public health · 2025Article
- The HbA1c/HDL-C ratio as a screening indicator of NAFLD in U.S. adults: a cross-sectional NHANES analysis (2017-2020).BMC gastroenterology · 2025Article
- Association between atherogenic index of plasma and all-cause mortality and cardiovascular disease among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.Diabetology & metabolic syndrome · 2025Article
- Association of cardiometabolic markers with hepatic steatosis and liver fibrosis in population without obesity and diabetes.Scientific reports · 2025Article
- Association of atherogenic index of plasma with kidney dysfunction in diabetic individuals: findings from two national population-based studies.BMC endocrine disorders · 2025Article
- Association of the atherogenic index of plasma with frailty in U.S. adults: a cross-sectional study based on NHANES.Lipids in health and disease · 2025Article
- Association between eGDR and MASLD and liver fibrosis: a cross-sectional study based on NHANES 2017-2023.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atherogenic Index of plasma (AIP) is closely related to metabolic abnormalities. But as of now, there is no definitive conclusion on the dose-response relationship pattern between AIP and metabolic associated fatty liver disease (MAFLD). Objective: The objective of this study was to provide a fresh insight for understanding the intrinsic link between AIP and the prevalence of MAFLD by exploring the dose-response pattern between AIP and MAFLD. Methods: A total of 9254 participants received the survey and 1090 participants were finally included according to the screening criteria. To evaluate the association between AIP and the prevalence of MAFLD based on weighted multivariate logistic regression. Sensitivity analysis of the association between AIP and MAFLD was performed using propensity score matching (PSM). Restrictive cubic splines (RCS) were used to identify patterns of dose-response relationships between AIP and MAFLD, and receiver operator characteristic (ROC) curves were used to evaluate the predictive ability of AIP and traditional lipid parameters for MAFLD. Results: In this study, a total of 563 participants were found to have MAFLD. The results of weighted multivariate logistic regression analysis demonstrated that, after adjusting for sex and age, participants in the highest quartile (Q4) of AIP had a significantly increased risk of developing MAFLD compared to those in the lowest quartile (Q1) (Model 2: OR = 9.03, 95% CI 4.75-17.17). A similar trend was observed in the fully adjusted model (Model 3: OR = 3.85, 95% CI 1.55-9.52). The RCS analysis revealed a linear dose-response association between AIP and MAFLD( Conclusion: A linear dose-response relationship exists between AIP and MAFLD, suggesting that as AIP increases, so does the risk of developing MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.